Therapeutic drug monitoring of vancomycin in patients receiving haemodialysis: Time for a change [4]

Journal of Clinical Pathology

Volumn 59, Issue 6, 2006, Pages 666-667

  Fitzpatrick, F ^a   McGaley, T ^a   Rajan, L ^a   Crowley, R ^a   Turley, M ^a   Humphreys, H ^a   Smyth, E ^a  

^a BEAUMONT HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

POLYCLONAL ANTIBODY; VANCOMYCIN;

BODY TEMPERATURE; DEGRADATION; DRUG MONITORING; DRUG USE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HEMODIALYSIS; LETTER; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; DRUG MONITORING; HUMANS; RENAL DIALYSIS; VANCOMYCIN;

EID: 33745069632     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. Follin SL, Mueller BA, Scott MK, et al. Falsely elevated serum vancomycin concentrations in hemodialysis patients. Am J Kidney Dis 1996;27:67-74.
2. Somerville AL, Wright DH, Rotschofer JC. Implications of vancomycin degradation products on therapeutic drug monitoring in patients with end-stage renal disease. Pharmacotherapy 1999;19:702-7.
3. Wilson JF, Davis AC, Tobin CM. Evaluation of commercial assays for vancomycin and aminoglycosides in serum: a comparison of accuracy and precision based on external quality assessment. J Antimicrob Chemother 2003;52:78-82.
4. Smith PF, Petros WP, Soucie MP, et al. New modified fluorescence polarization immunoassay does not falsely elevate vancomycin concentrations in patients with end-stage renal disease. Ther Drug Monit 1998;20:231-5.
5. Tobin CM, Darville JM, Thomson AH, et al. Vancomycin therapeutic drug monitoring: is there a consensus view? The results of a UK National External Quality Assessment Scheme (UK NEQAS) for Antibiotic Assays Questionnaire. J Antimicrob Chemother 2002;50:713-8.